Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

$1–2 Per Month Could Help Solve Access To Essential Medicines Problem, Experts Say

Executive Summary

Just $13 a year could provide a basic set of affordable medicines to all people in low- and middle-income countries, experts commissioned by The Lancet say in a report calling for better access to essential medicines. But views differ as to whether all the recommendations in the report are appropriate or go far enough to address the roots of the problem.

You may also be interested in...



UN Panel Report: Positions Still Polarized Over Medicines Access Barriers

The report by the independent panel shows that the companies that develop and produce medicines, and the non-governmental organizations working on health issues at local level, still disagree fundamentally on the best way to go about improving access to those medicines. While R&D firms are skeptical of the report’s recommendations, the feeling among NGOs seems to be that this report represents something of a landmark development in the access debate.

‘No Turning Back’ On Regulatory Changes at UK MHRA

The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.

EU Politicians: 'Bring Pharma Manufacturing Back To Europe'

The pharmaceutical industry has given a muted welcome to proposals for building up the EU's resilience to medicine shortages, saying many of the ideas will not tackle the root causes of supply problems and could even serve to undermine innovation. 

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel